Acute Dyspnoea

  • Rachel WisemanEmail author
Reference work entry


Acute (or episodic) dyspnoea is a debilitating symptom that induces fear and anxiety in patients and family/carers alike. Management focuses on addressing the underlying cause where this can be identified. In addition to addressing reversible causes, management of acute dyspnoea or a dyspnoea crisis will be discussed. Evidence for both pharmacological and non-pharmacological management strategies is outlined, with discussion of how these can be incorporated into a comprehensive, individualized management plan. Involvement and education of the wider interdisciplinary team across healthcare settings is essential. This chapter will also cover some of the more specific causes of acute dyspnoea such as anxiety or breathing pattern disorders, stridor or upper airway obstruction, bronchospasm, and the sensation of choking with a focus on neuromuscular diseases.


  1. Abernethy AP, et al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. Lancet. 2010;376:784–93.CrossRefGoogle Scholar
  2. Bailey PH. The dyspnea-anxiety-dyspnea cycle- COPD patients’ stories of breathlessness: “it’s scary when you can’t breathe”. Qual Health Res. 2004;14(6):760–78.CrossRefGoogle Scholar
  3. Banfi P, et al. A review of options for treating sialorrhea in amyotrophic lateral sclerosis. Respir Care. 2015;60(3):446–54.CrossRefGoogle Scholar
  4. Boulding R, et al. Dysfunctional breathing: a review of the literature and proposal for classification. Eur Respir Rev. 2016;25:287–94.CrossRefGoogle Scholar
  5. Cabezon-Gutierrez L, et al. Opioids for management of episodic breathlessness or dyspnea in patients with advanced disease. Support Care Cancer. 2016;24:4045–55.CrossRefGoogle Scholar
  6. Cates CJ, et al. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev. 2013;9:CD000052.Google Scholar
  7. Chang AS, et al. Prospective use of descriptors of dyspnea to diagnose common respiratory diseases. Chest. 2015;148(4):895–902.CrossRefGoogle Scholar
  8. Currow DC, et al. Do the trajectories of dyspnea differ in prevalence and intensity by diagnosis at the end of life? A consecutive cohort study. J Pain Symptom Manage. 2010;39(4):680–90.CrossRefGoogle Scholar
  9. Diehl JL, et al. Helium in the adult critical care setting. Ann Intensive Care. 2011;1:24.CrossRefGoogle Scholar
  10. Ek K, et al. “The unpredictable death” – the last year of life for patients with advanced COPD: relatives stories. Palliat Support Care. 2015;13:1213–22.CrossRefGoogle Scholar
  11. Farquar M, et al. Six key topics informal carers of patients with breathlessness in advanced disease want to learn about and why: MRC phase 1 study to inform an educational intervention. PLoS One. 2017;12(5):e0177081.CrossRefGoogle Scholar
  12. Flockton RJ, et al. Use of nebulised adrenaline in the management of steroid resistant stridor. Palliat Med. 2007;21:723–4.CrossRefGoogle Scholar
  13. Giacomini M, et al. Experiences of living and dying with COPD: a systematic review and synthesis of the qualitative empirical literature. Ont Health Technol Assess Ser. 2012;12(13):1–47.PubMedPubMedCentralGoogle Scholar
  14. Godbout K, et al. A distress protocol for respiratory emergencies in terminally ill patients with lung cancer or chronic obstructive pulmonary disease. Am J Hosp Palliat Med. 2016;33(9):817–22.CrossRefGoogle Scholar
  15. Guibert N, et al. Techniques of endoscopic airway tumour treatment. J Thorac Dis. 2016;8(11):3343–60.CrossRefGoogle Scholar
  16. Gysels MH, Higginson IJ. The lived experience of breathlessness and its implications for care: a qualitative comparison in cancer, COPD, heart failure and MND. BMC Palliat Care. 2011;10:15.CrossRefGoogle Scholar
  17. Hadjikoutis S, et al. Coughing and choking in motor neuron disease. J Neurol Neurosurg Psychiatry. 2000;68:601–4.CrossRefGoogle Scholar
  18. Hardy J, et al. A randomised, double-blind controlled trial of intranasal midazolam for the palliation of dyspnoea in patients with life-limiting disease. Support Care Cancer. 2016;24(7):3069–76.PubMedGoogle Scholar
  19. Harris P, Nagy S, Vardaxis N. Mosby’s dictionary of medicine, nursing and health professions. Marrickville: Elsevier; 2014.Google Scholar
  20. Hearson, et al. Sleeping with one eye open: the sleep experience of family members providing palliative care at home. J Palliat Care. 2011;27(2):69–78.CrossRefGoogle Scholar
  21. Hutchinson A, et al. Breathlessness and presentation to the emergency department: a survey and clinical record review. BMC Pulm Med. 2017;17:53–9.CrossRefGoogle Scholar
  22. Janssens, et al. Dyspnoea perception in COPD: association between anxiety, dyspnoea-related fear and dyspnoea in a pulmonary rehabilitation program. Chest. 2011;140(3):618–25.CrossRefGoogle Scholar
  23. Jennings AL, et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2002;57:939–44.CrossRefGoogle Scholar
  24. Linkins LA, Takach Lapner S. Review of D dimer testing: good, bad and ugly. Int J Lab Hematol. 2017;39(Suppl 1):98–103.CrossRefGoogle Scholar
  25. LOTT Group. A randomised trial of long-term oxygen for COPD with moderate desaturation. N Engl J Med. 2016;375:1617–27.CrossRefGoogle Scholar
  26. Luckett T, et al. Content and quality of websites supporting self-management of chronic breathlessness in advanced illness: a systematic review. Prim Care Respir Med. 2016;26:16025.CrossRefGoogle Scholar
  27. MacPherson A, et al. The views of patients with severe chronic obstructive pulmonary disease on advance care planning: a qualitative study. Palliat Med. 2012;27(3):265–72.CrossRefGoogle Scholar
  28. McGeachen AJ, et al. A multicentre evaluation of oropharyngeal secretion management practices in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017a;18:1–9.CrossRefGoogle Scholar
  29. McGeachen AJ, et al. Management of oral secretions in neurological disease. Pract Neurol. 2017b;17:96–103.CrossRefGoogle Scholar
  30. Mularski, et al. An official American thoracic society workshop report: assessment and palliative management of dyspnea crisis. Ann Am Thorac Soc. 2013a;10(5):S98–S106.CrossRefGoogle Scholar
  31. Mularski, et al. ATS dyspnoea crisis supplementary methods document and evidence summary. Ann Am Thorac Soc. 2013b;10(5). Online supplement date of access 7th Feb 2017.Google Scholar
  32. Neudert C, et al. The course of the terminal phase in patients with amyotrophic lateral sclerosis. J Neurol. 2001;248:612–6.CrossRefGoogle Scholar
  33. Ost DE, et al. Therapeutic bronchoscopy for malignant central airway obstruction. Chest. 2015;147(5):1282–98.CrossRefGoogle Scholar
  34. Parshall MB, et al. Dyspnea duration, distress and intensity in emergency department visits for heart failure. Heart Lung. 2001;30(1):47–56.CrossRefGoogle Scholar
  35. Parshall MB, et al. An official ATS society statement: update on the mechanisms, assessment and management of dyspnea. Am J Respir Crit Care Med. 2012;185(4):435–52.CrossRefGoogle Scholar
  36. Reddy SK, et al. Characteristics and correlates of dyspnoea in patients with advanced cancer. J Palliat Med. 2009;12(1):29–36.CrossRefGoogle Scholar
  37. Remi C, et al. Pharmacological management of bronchorrhea in malignant disease: a systematic literature review. J Pain Symptom Manage. 2016;51(5):916–25.CrossRefGoogle Scholar
  38. Simon ST, et al. Episodic and continuous breathlessness: a new categorization of breathlessness. J Pain Symptom Manage. 2013a;45(6):1019–29.CrossRefGoogle Scholar
  39. Simon ST, et al. Episodic breathlessness in patients with advanced disease: a systematic review. J Pain Symptom Manage. 2013b;45(3):561–77.CrossRefGoogle Scholar
  40. Simon ST, et al. Episodes of breathlessness: types and patterns – a qualitative study exploring experiences of patients with advanced diseases. Palliat Med. 2013c;27(6):524–32.CrossRefGoogle Scholar
  41. Simon ST, et al. Fentanyl for the relief of refractory breathlessness: a systematic review. J Pain Symptom Manage. 2013d;46(6):874–86.CrossRefGoogle Scholar
  42. Simon ST, et al. Definition, categorization, and terminology of episodic breathlessness: consensus by and international Delphi survey. J Pain Symptom Manage. 2014;47(5):828–38.CrossRefGoogle Scholar
  43. Simon ST, et al. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev. 2016;10:Art no CD007354.Google Scholar
  44. Smith SW, Biros M. Relief of imminent respiratory failure from upper airway obstruction by use of helium-oxygen: a case series and brief review. Acad Emerg Med. 1999;6(9):953–6.CrossRefGoogle Scholar
  45. Weingartner V, et al. Characterizing episodic breathlessness in patients with advanced disease. J Palliat Med. 2013;16(10):1275–9.CrossRefGoogle Scholar
  46. Weingartner V, et al. Characteristics of episodic breathlessness as reported by patients with advanced chronic obstructive pulmonary disease and lung cancer: results of a descriptive cohort study. Palliat Med. 2015;29(5):420–8.CrossRefGoogle Scholar
  47. Wimalasena Y, et al. Lung ultrasound: a useful tool in the assessment of the dyspnoeic patient in the emergency department. Fact or fiction? Emerg Med J. 2017;0:1–9.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Canterbury District Health BoardChristchurchNew Zealand

Personalised recommendations